A Phase 2 interventional study of Alirocumab and Matching placebo in Carotid Artery Stenosis, sponsored by Middle East North Africa Stroke and Interventional Neurotherapies Organization. Completed at 5 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Middle East North Africa Stroke and Interventional Neurotherapies Organization · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
CAROTID STABILISE Pilot tested whether adding alirocumab to high-intensity atorvastatin changes high-risk plaque features in people recently affected by a stroke or transient ischemic attack (TIA) related to carotid artery narrowing. Forty adults aged 40-80 years were randomly assigned in equal groups to alirocumab 150 mg injected under the skin every two weeks or matching placebo every two weeks; both groups took atorvastatin 80 mg daily for 26 weeks. The main outcome was change from baseline to week 26 in intraplaque haemorrhage (IPH) volume measured by high-resolution carotid MRI. Other outcomes included changes in plaque features and LDL cholesterol, safety events, and exploratory recurrent ischemic events or carotid revascularisation. The study was conducted at five sites-four in Egypt and one in Istanbul, Türkiye-and completed on 26 August 2026. This ClinicalTrials.gov record is being submitted retrospectively after study completion; prospective registration on ClinicalTrials.gov is not claimed.
CAROTID STABILISE Pilot was a prospective, multicentre, randomized, double-blind, placebo-controlled, parallel-group pilot trial conducted at five sites: four in Egypt and one in Istanbul, Türkiye. Forty adults aged 40-80 years with recently symptomatic carotid stenosis and high-risk plaque features on MRI were assigned 1:1 to alirocumab 150 mg subcutaneously every two weeks plus atorvastatin 80 mg orally once daily, or matched placebo plus atorvastatin 80 mg orally once daily, for 26 weeks. The protocol described quadruple masking of participants, care providers, investigators, and outcome assessors. The primary outcome was absolute change in carotid intraplaque haemorrhage (IPH) volume from baseline to week 26, measured in mm³ by 3T high-resolution vessel-wall MRI with blinded central assessment. Secondary outcomes included percentage change in IPH volume; absolute and percentage change in lipid-rich necrotic core volume; change in total wall plaque volume and plaque burden; and change in LDL cholesterol and other lipid parameters. Safety outcomes included treatment-emergent adverse events, serious adverse events, and injection-site reactions. Exploratory clinical assessments included recurrent ipsilateral ischemic stroke or TIA and carotid revascularisation. Signed and approved Amendment 1-Clarification/Correction, document MENASINO-CAROTID-PILOT-AMD1, Version 1.0, dated and effective 1 December 2025, states that this 40-participant pilot is a separate stand-alone trial, has separate ethics approvals and registration, and is excluded from parent Phase III trial NCT07586540. The pilot enrolled participants beginning 6 January 2026; the final week-26 MRI assessment and final required safety follow-up occurred on 26 August 2026. This ClinicalTrials.gov record is being submitted retrospectively after enrollment and follow-up were complete. The study was not prospectively registered on ClinicalTrials.gov, and no claim of prospective ClinicalTrials.gov registration is made.
366 studies on the registry are indexed under Carotid Stenosis; 86 are open to participants now.
This study's enrollment of 40 is below the median of 103 across 191 interventional studies indexed under Carotid Stenosis.
Browse Carotid Stenosis studies →Middle East North Africa Stroke and Interventional Neurotherapies Organization is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alirocumab 150 mg by subcutaneous injection every 2 weeks for 26 weeks, with atorvastatin 80 mg orally once daily as background therapy.
Drug: Alirocumab
Matched placebo by subcutaneous injection every 2 weeks for 26 weeks, with atorvastatin 80 mg orally once daily as background therapy.
Drug: Matching placebo
Alirocumab 150 mg administered by subcutaneous injection every 2 weeks for 26 weeks. Participants also received atorvastatin 80 mg orally once daily as background therapy.
Matching placebo administered by subcutaneous injection every 2 weeks for 26 weeks. Participants also received atorvastatin 80 mg orally once daily as background therapy.
Absolute change in carotid intraplaque haemorrhage (IPH) volume
Change in IPH volume (week 26 minus baseline), measured in mm³ by 3T high-resolution vessel-wall MRI and assessed by a blinded central imaging laboratory. Negative values indicate a decrease in IPH volume.
Time frame: Baseline to Week 26
Percentage change in carotid intraplaque haemorrhage (IPH) volume
Percentage change in IPH volume from baseline to week 26, assessed by 3T high-resolution vessel-wall MRI with blinded central imaging assessment.
Time frame: Baseline to Week 26
Absolute change in carotid lipid-rich necrotic core (LRNC) volume
Absolute change in LRNC volume from baseline to week 26, measured by high-resolution carotid MRI and blinded central imaging assessment.
Time frame: Baseline to Week 26
Percentage change in carotid lipid-rich necrotic core (LRNC) volume
Percentage change in LRNC volume from baseline to week 26, assessed on high-resolution carotid MRI with blinded central imaging assessment.
Time frame: Baseline to Week 26
Change in total carotid wall plaque volume
Change in total wall plaque volume from baseline to week 26, measured in mm³ by high-resolution carotid MRI with blinded central imaging assessment.
Time frame: Baseline to Week 26
Change in carotid plaque burden
Change in plaque burden, expressed in percentage points, from baseline to week 26 and assessed by high-resolution carotid MRI.
Time frame: Baseline to Week 26
Change in LDL cholesterol and other lipid parameters
Change in LDL cholesterol (absolute and percentage change) and other lipid parameters, including total cholesterol, from baseline to week 26.
Time frame: Baseline to Week 26
Treatment-emergent adverse events and serious adverse events
Number of participants experiencing treatment-emergent adverse events, serious adverse events, or injection-site reactions during the study period.
Time frame: From first study treatment through Week 26
Exploratory ipsilateral recurrent ischemic stroke or TIA and carotid revascularisation
Occurrence of ipsilateral recurrent ischemic stroke or TIA and carotid revascularisation through week 26. These exploratory clinical events were not powered for efficacy.
Time frame: Randomization through Week 26
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Aug 2026, 7 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab
Middle East North Africa Stroke and Interventional Neurotherapies Organization